News & Updates

Empagliflozin plus GLP-1RA prevents hospitalization, death in adults with T2D
Empagliflozin plus GLP-1RA prevents hospitalization, death in adults with T2D
17 Sep 2024 byStephen Padilla

Patients with type 2 diabetes (T2D) who initiated treatment with empagliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), and a glucagon-like peptide-1 receptor agonist (GLP-1RA) show reduced hospitalization for heart failure (HHF) and all-cause mortality risks relative to those treated with empagliflozin and dipeptidyl peptidase-4 inhibitors (DPP-4i), reports a study presented at EASD 2024.

Empagliflozin plus GLP-1RA prevents hospitalization, death in adults with T2D
17 Sep 2024
GLP-1RA prevents glaucoma development in T2D patients
GLP-1RA prevents glaucoma development in T2D patients
17 Sep 2024
GLP-1 RA benefit may branch out into obesity-related cancers
GLP-1 RA benefit may branch out into obesity-related cancers
17 Sep 2024 byAudrey Abella

Another feather may have been added in the cap of glucagon-like protein-1 receptor agonists (GLP-1 RAs) – the class of type 2 diabetes (T2D) drugs that has become a blockbuster recently due to their remarkable weight loss benefit – as evidence of their potential to reduce the risk of obesity-associated cancers (OACs) comes to light.

GLP-1 RA benefit may branch out into obesity-related cancers
17 Sep 2024
COVID-19 variants carry no increased autoimmune sequelae risk
COVID-19 variants carry no increased autoimmune sequelae risk
16 Sep 2024 byJairia Dela Cruz

COVID-19 variants delta and omicron BA.1 or BA.2 do not pose a substantial threat of long-term autoimmune complications, except for a modest elevation in inflammatory bowel disease and bullous skin disorders among hospitalized patients during the omicron predominance in Singapore, as shown in a study.

COVID-19 variants carry no increased autoimmune sequelae risk
16 Sep 2024
Cruciferous vegetables help avert recurrence in NMIBC patients on BCG
Cruciferous vegetables help avert recurrence in NMIBC patients on BCG
16 Sep 2024